FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4322763048> ?p ?o ?g. }

• W4322763048 endingPage "566" @default.
• W4322763048 startingPage "560" @default.
• W4322763048 abstract "The aims of this study were to evaluate the relationship of clinical and imaging baseline factors and treatment on the occurrence of early neurological improvement (ENI) in the WAKE-UP trial of MRI-guided intravenous thrombolysis in unknown onset stroke and to examine the association of ENI with long-term favorable outcome in patients treated with intravenous thrombolysis.We analyzed data from all patients with at least moderate stroke severity, reflected by an initial National Institutes of Health Stroke Scale (NIHSS) score ≥4 randomized in the WAKE-UP trial. ENI was defined as a decrease in NIHSS of ≥8 or a decline to zero or 1 at 24 h after initial presentation to the hospital. Favorable outcome was defined as a modified Rankin Scale score of 0-1 at 90 days. We performed group comparison and multivariable analysis of baseline factors associated with ENI and performed mediation analysis to evaluate the effect of ENI on the relationship between intravenous thrombolysis and favorable outcome.ENI occurred in 93 out of 384 patients (24.2%) and was more likely to occur in patients who received treatment with alteplase (62.4% vs. 46.0%, p = 0.009), had smaller acute diffusion-weighted imaging lesion volume (5.51 mL vs. 10.9 mL, p ≤ 0.001), and less often large-vessel occlusion on initial MRI (7/93 [12.1%] versus 40/291 [29.9%], p = 0.014). In multivariable analysis, treatment with alteplase (OR 1.97, 95% confidence interval [CI] 0.954-1.100), lower baseline stroke volume (OR 0.965, 95% CI: 0.932-0.994), and shorter time from symptom recognition to treatment (OR 0.994, 95% CI: 0.989-0.999) were independently associated with ENI. Patients with ENI had higher rates of favorable outcome at 90-day follow-up (80.6% vs. 31.3%, p ≤ 0.001). The occurrence of ENI significantly mediated the association of treatment with a good outcome, with ENI at 24 h explaining 39.4% (12.9-96%) of the treatment effect.Intravenous alteplase increases the odds of ENI in patients with at least moderate stroke severity, especially when given early. In patients with large-vessel occlusion, ENI is rarely observed without thrombectomy. ENI represents a good surrogate early marker of treatment effect as more than a third of good outcome at 90 days is explained by ENI at 24 h." @default.
• W4322763048 created "2023-03-03" @default.
• W4322763048 creator A5001101402 @default.
• W4322763048 creator A5007233811 @default.
• W4322763048 creator A5008206204 @default.
• W4322763048 creator A5008694192 @default.
• W4322763048 creator A5013144930 @default.
• W4322763048 creator A5022547539 @default.
• W4322763048 creator A5024501356 @default.
• W4322763048 creator A5025865872 @default.
• W4322763048 creator A5034616919 @default.
• W4322763048 creator A5036657027 @default.
• W4322763048 creator A5040167459 @default.
• W4322763048 creator A5042205473 @default.
• W4322763048 creator A5048979802 @default.
• W4322763048 creator A5049975927 @default.
• W4322763048 creator A5050159846 @default.
• W4322763048 creator A5050742821 @default.
• W4322763048 creator A5061175108 @default.
• W4322763048 creator A5065179101 @default.
• W4322763048 creator A5076351525 @default.
• W4322763048 creator A5087309123 @default.
• W4322763048 date "2023-01-01" @default.
• W4322763048 modified "2023-10-05" @default.
• W4322763048 title "Predictors of Early Neurological Improvement and Its Relationship to Thrombolysis Treatment and Long-Term Outcome in the WAKE-UP Study" @default.
• W4322763048 cites W1908991493 @default.
• W4322763048 cites W1951462188 @default.
• W4322763048 cites W1963816081 @default.
• W4322763048 cites W1971440513 @default.
• W4322763048 cites W1996422166 @default.
• W4322763048 cites W2010143351 @default.
• W4322763048 cites W2030895694 @default.
• W4322763048 cites W2033053304 @default.
• W4322763048 cites W2048026837 @default.
• W4322763048 cites W2048480423 @default.
• W4322763048 cites W2077992344 @default.
• W4322763048 cites W2081383358 @default.
• W4322763048 cites W2088823179 @default.
• W4322763048 cites W2098121633 @default.
• W4322763048 cites W2114950471 @default.
• W4322763048 cites W2121854361 @default.
• W4322763048 cites W2139202032 @default.
• W4322763048 cites W2150649620 @default.
• W4322763048 cites W2431132677 @default.
• W4322763048 cites W2465022435 @default.
• W4322763048 cites W2803802119 @default.
• W4322763048 cites W2886965204 @default.
• W4322763048 cites W2903114284 @default.
• W4322763048 cites W2924359439 @default.
• W4322763048 cites W2977259802 @default.
• W4322763048 cites W2991979046 @default.
• W4322763048 cites W2996125082 @default.
• W4322763048 cites W3011565092 @default.
• W4322763048 cites W3098536600 @default.
• W4322763048 cites W3150269948 @default.
• W4322763048 doi "https://doi.org/10.1159/000528805" @default.
• W4322763048 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36863328" @default.
• W4322763048 hasPublicationYear "2023" @default.
• W4322763048 type Work @default.
• W4322763048 citedByCount "0" @default.
• W4322763048 crossrefType "journal-article" @default.
• W4322763048 hasAuthorship W4322763048A5001101402 @default.
• W4322763048 hasAuthorship W4322763048A5007233811 @default.
• W4322763048 hasAuthorship W4322763048A5008206204 @default.
• W4322763048 hasAuthorship W4322763048A5008694192 @default.
• W4322763048 hasAuthorship W4322763048A5013144930 @default.
• W4322763048 hasAuthorship W4322763048A5022547539 @default.
• W4322763048 hasAuthorship W4322763048A5024501356 @default.
• W4322763048 hasAuthorship W4322763048A5025865872 @default.
• W4322763048 hasAuthorship W4322763048A5034616919 @default.
• W4322763048 hasAuthorship W4322763048A5036657027 @default.
• W4322763048 hasAuthorship W4322763048A5040167459 @default.
• W4322763048 hasAuthorship W4322763048A5042205473 @default.
• W4322763048 hasAuthorship W4322763048A5048979802 @default.
• W4322763048 hasAuthorship W4322763048A5049975927 @default.
• W4322763048 hasAuthorship W4322763048A5050159846 @default.
• W4322763048 hasAuthorship W4322763048A5050742821 @default.
• W4322763048 hasAuthorship W4322763048A5061175108 @default.
• W4322763048 hasAuthorship W4322763048A5065179101 @default.
• W4322763048 hasAuthorship W4322763048A5076351525 @default.
• W4322763048 hasAuthorship W4322763048A5087309123 @default.
• W4322763048 hasConcept C126322002 @default.
• W4322763048 hasConcept C127413603 @default.
• W4322763048 hasConcept C164705383 @default.
• W4322763048 hasConcept C168563851 @default.
• W4322763048 hasConcept C2779581417 @default.
• W4322763048 hasConcept C2780645631 @default.
• W4322763048 hasConcept C2780931571 @default.
• W4322763048 hasConcept C3020199598 @default.
• W4322763048 hasConcept C44249647 @default.
• W4322763048 hasConcept C500558357 @default.
• W4322763048 hasConcept C541997718 @default.
• W4322763048 hasConcept C71924100 @default.
• W4322763048 hasConcept C78519656 @default.
• W4322763048 hasConceptScore W4322763048C126322002 @default.
• W4322763048 hasConceptScore W4322763048C127413603 @default.
• W4322763048 hasConceptScore W4322763048C164705383 @default.
• W4322763048 hasConceptScore W4322763048C168563851 @default.

• next